Levadex, MAP Pharmaceuticals’ orally inhaled medication for acute migraine, has met all 4 of the Phase 3 endpoints. In a news release issued on May 26, 2009 MAP Pharmaceuticals stated,
Patients taking LEVADEX therapy (formerly referred to as MAP0004) had statistically significant improvement at two hours compared to patients on placebo for each of the primary endpoints: Pain relief,…Phonophobia… Photophobia,…and Nausea….
Relief from nausea was particularly notable with more than two thirds of the study population gaining relief.
The Phase 3 study population of 792 Migraine sufferers had more severe migraine pain than expected with 100% experiencing moderate or severe pain.